New insights of altered lipid profile in Fragile X Syndrome.
BACKGROUND
Fragile X Syndrome (FXS) is the main genetic cause of autism and intellectual deficiency resulting the absence of the Fragile X Mental Retardation Protein (FMRP). Clinical picture is characterized by cognitive impairment associated with a broad spectrum of psychiatric comorbidities including autism spectrum disorders and attention-deficit/hyperactivity disorders. Some of these disorders have been associated with lipid abnormalities and lower cholesterol levels. Since lipids are important for neuronal development, we aim to investigate the lipid profile of French Canadian-FXS individuals and to identify the altered components of cholesterol metabolism as well as their association with clinical profile.


METHODS
Anthropometric data were collected from 25 FXS individuals and 26 controls. Lipid assessment included: total cholesterol (TC), triglycerides, LDL, HDL, ApoB, ApoA1, PCSK9, Lp(a) and lipoprotein electrophoresis. Aberrant and adaptive behaviour of affected individuals was respectively assessed by the ABC-C and ABAS questionnaires.


RESULTS
FXS participants had a higher body mass index as compared to controls while 38% of them had TC<10th percentile. Lower levels of LDL, HDL and apoA1 were observed in FXS group as compared to controls. However, PCSK9 levels did not differ between the two groups. As expected, PCSK9 levels correlated with total cholesterol (rs = 0.61, p = 0.001) and LDL (rs = 0.46, p = 0.014) in the control group, while no association was present in the FXS group. An inverse relationship was observed between total cholesterol and aberrant behaviour as determined by ABC-C total score.


CONCLUSIONS
Our results showed the presence of hypocholesterolemia in French Canadian-FXS population, a condition that seems to influence their clinical phenotype. We identified for the first time a potential underlying alteration of PCSK9 function in FXS that could result from the absence of FMRP. Further investigations are warranted to better understand the association between cholesterol metabolism, PCSK9, FMRP and clinical profile.
Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Artuela
http://orcid.org/0000-0002-9485-7245
A
Çaku
Nabil G. Seidah, Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute, affiliated to the Université de Montréal, Montréal, Québec, Canada.
Nabil G
NG
Seidah
Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Audrey
A
Lortie
Department of Paediatrics, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Nancy
N
Gagné
Department of Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Patrice
P
Perron
Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Jean
J
Dubé
Department of Biochemistry, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Francois
F
Corbin
D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D015992:Body Mass Index; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005600:Fragile X Syndrome / Q000097:blood* / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008297:Male; D000071449:Proprotein Convertase 9 / Q000097:blood; D014280:Triglycerides / Q000097:blood; D055815:Young Adult
C505693:APOA1 protein, human; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9